Clinical trial register · European Union · CTIS

EU Clinical Trials Tracker

Name: EU clinical trials authorised under CTIS
Creator: Priya Life Science
License: https://www.ema.europa.eu/en/about-us/legal-notice

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12777 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Nov 2026, 03:17 UTC

2556

Shown in this register

most recently authorised

12,777

Total on CTIS

full historical archive

789

Phase III

within the shown window

Top member states

Spain 1075 France 930 Germany 898 Italy 778 Poland 619 Netherlands 547

Narrow the registerReset

Search within results

Phase

Lead sponsor

Clear sponsor filter

Member state

All 28 states

Trials in this register

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase I

A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults

2026-527480-15-00Alzheimer’s Disease

Pfizer Inc.

Nervous System Diseases

Belgium

05/11/2026

Phase III

B7981110 A Phase 3, randomized, double blind, placebo controlled study to investigate the safety and efficacy of ritlecitinib in adult and adolescent participants 12 years of age and older with moderate alopecia areata

2026-526355-62-00Moderate alopecia areata (AA)

Pfizer Inc.

Immune System Diseases

Poland, France

26/10/2026

Phase III

C5701009 - A Phase 3, Open-label, Randomized Study To Evaluate Enfortumab Vedotin in Combination with Pembrolizumab in Adult participants with Muscle-Invasive Bladder Cancer Who Are Ineligible for or have elected not to undergo cystectomy

2026-525612-34-00Muscle-Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Pembrolizumab

Pfizer Inc.

Female Urogenital Diseases and Pregnancy Complications

France, Spain, Italy, Germany

15/10/2026

Phase III

C3671017 A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE IN CHILDREN AT HIGH RISK OF RSV DISEASE

2026-525797-19-00Prevention of lower respiratory tract disease caused by res…

DrugVaxzevria

Pfizer Inc.

Respiratory Tract Diseases

Spain, Poland

01/10/2026

Phase I

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 are Tolerated and Act in the Body in Healthy Adults or Adults With Mild-to-Moderate Asthma

2026-526260-21-00Atopic dermatitis, asthma and other type 2 inflammatory dis…

Pfizer Inc.

Immune System Diseases

Belgium

30/09/2026

Phase III

C4931004 - A Phase 3, Randomized Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Catch-Up Vaccination Regimen of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Children and Adolescents

2025-523445-10-00Pneumoccoccal Immunisation

Pfizer Inc.

Bacterial Infections and Mycoses

Poland, Finland

28/09/2026

Phase I

A Study to Learn About the Study Medicine Called PF-08032562 in People with Advanced or Metastatic Solid Tumors

2025-524387-38-00metastatic/advanced breast cancer (BC) and colorectal cance…

Pfizer Inc.

Neoplasms

France, Spain

25/09/2026

Phase III

C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)

2026-525318-75-00Overweight or Obesity

Pfizer Inc.

Nutritional and Metabolic Diseases

Spain, France, Germany, Poland, Italy

09/09/2026

Phase I

A Study to Learn How Different Manufactured Products of the Study Medicine Called Osivelotor (PF-07940367) Taste and Are Taken Up Into the Blood When Mixed With Soft Foods or Liquids Given on an Empty Stomach or Given With Food or an Acid Reducing Agent in Healthy Adults

2024-511410-20-01Sickle Cell Disease

Pfizer Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Belgium

07/09/2026

Phase II

C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer

2025-524825-42-00Early-Stage Resectable or Locally Advanced Unresectable Non…

Pfizer Inc.

Neoplasms

Spain, France, Italy, Ireland, Germany, Poland

26/08/2026

Phase III

C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

2025-523447-35-02Pneumoccoccal Immunisation

Pfizer Inc.

Bacterial Infections and Mycoses

Spain, Finland, Poland, Germany, Greece, Hungary, Italy

17/08/2026

Phase I

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

2025-522532-14-00Advanced solid tumors

Pfizer Inc.

Neoplasms

Netherlands, France, Spain

11/08/2026

Phase III

C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

2025-524717-86-00LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JU…

Pfizer Inc.

Neoplasms

France, Spain, Italy

07/07/2026

Phase I

C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity

2026-526334-67-00chronic weight management and other weight-related co-morbi…

Pfizer Inc.

Nutritional and Metabolic Diseases

Belgium

01/07/2026

Phase II

C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

2025-524686-24-00Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Spain

29/06/2026

Phase I

A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and Patients

2025-524150-34-00Atopic Dermatitis

Pfizer Inc.

Skin and Connective Tissue Diseases

Poland

18/06/2026

Phase I

A Study to Learn About How Different Forms of Study Medicine Prifetrastat are Taken Up Into the Blood in Healthy Adults

2026-526038-26-00Locally advanced or metastatic ER+/HER2- breast cancer

Pfizer Inc.

Neoplasms

Belgium

17/06/2026

Phase II

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

2024-518587-12-00MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (C…

Pfizer Inc.

Respiratory Tract Diseases

Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary

08/06/2026

Phase I/II

C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.

2025-523523-21-00Locally Advanced or Metastatic Urothelial Cancer

Pfizer Inc.

Neoplasms

Netherlands, Spain

29/05/2026

Phase I

A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

2025-525125-12-00Migraine with or without aura

Pfizer Inc.

Nervous System Diseases

Belgium

28/04/2026

Phase I/II

C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

2025-523524-53-00ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Pfizer Inc.

Neoplasms

Germany, Spain

21/04/2026

Phase III

C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY

2025-523660-21-00severe to moderately severe hemophilia B (FIX:C ≤ 2%), hemo…

Pfizer Inc.

Hemic and Lymphatic Diseases

Italy, Germany, France, Spain, Sweden, Greece

20/04/2026

Phase II

C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

2025-522965-31-00Atopic Dermatitis

Pfizer Inc.

Skin and Connective Tissue Diseases

Poland, Czechia, Germany, Bulgaria, France

14/04/2026

Phase I/II

C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors

2025-523526-40-00Advanced Solid Tumors

Pfizer Inc.

Neoplasms

Italy, Spain, France, Germany

09/04/2026

Phase I/II

C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

2025-523525-17-00Unresectable Locally Advanced or Metastatic Hepatocellular …

DrugsPF-08634404·Ipilimumab

Pfizer Inc.

Neoplasms

Spain, Italy, Germany, France

09/04/2026

Phase III

C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

2025-523522-41-00Extensive-Stage Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Atezolizumab·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Germany, Spain

07/04/2026

Phase I

A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up into the Blood of Healthy Adults After Taking Different Tablets of the Study Medicine Called Ibuzatrelvir.

2025-525041-43-00Coronavirus disease 2019

Pfizer Inc.

Virus Diseases

Belgium

01/04/2026

Phase I

A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin® (somatropin) Delivery and Taken Up Into the Blood in Healthy Adults

2026-525165-52-00Growth hormone deficiency

Pfizer Inc.

Hormonal diseases

Belgium

25/03/2026

Phase III

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

2025-523461-17-01LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Pfizer Inc.

Neoplasms

France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany

24/03/2026

Phase III

C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

2025-523521-18-00Metastatic Colorectal Cancer

DrugsPF-08634404·Calcium folinate·Fluorouracil·Oxaliplatin

Pfizer Inc.

Neoplasms

Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark

23/03/2026

Phase I

A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 are Tolerated and Act in the Body of Healthy Adults

2025-523759-76-01Rheumatoid arthritis and Systemic Lupus Erythematosus

Pfizer Inc.

Immune System Diseases

Belgium

17/03/2026

Phase I

A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 mg Tablet in Healthy Adults Under Fed Conditions

2026-525342-29-00Transthyretin amyloidosis

Pfizer Inc.

Pathological Conditions, Signs and Symptoms

Belgium

11/03/2026

Phase II

B7981119 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Evaluating the Safety and Efficacy of Ritlecitinib (PF-06651600) in Adults with Moderate to Severe Hidradenitis Suppurativa

2025-522705-37-00HIDRADENITIS SUPPURATIVA

Pfizer Inc.

Skin and Connective Tissue Diseases

Germany, Poland, Spain, Greece

11/03/2026

Phase I

C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.

2025-521756-39-00Non-muscle invasive bladder cancer (NMIBC)

Pfizer Inc.

Neoplasms

France, Spain

02/03/2026

Phase II

C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis

2025-523100-77-00Ulcerative Colitis

Pfizer Inc.

Digestive System Diseases

Finland, Poland, France, Germany, Italy, Slovakia

27/02/2026

Phase II

B7981118 - A Phase 2b Randomized, Double Blind, 12-Week Placebo Controlled Study With a 12-Week Double-Blind Extension Period to Evaluate the Efficacy, Safety and Tolerability of Ritlecitinib (PF 06651600) in Adult Participants with Chronic Spontaneous Urticaria

2025-522642-44-00CHRONIC SPONTANEOUS URTICARIA

Pfizer Inc.

Immune System Diseases

Spain, Germany, Bulgaria, Poland

25/02/2026

Phase I

C5951001- A Phase 1 Study of PF-08046876 in Participants with Advanced Solid Tumors.

2025-521729-33-00advanced solid tumors

Pfizer Inc.

Neoplasms

Spain

23/12/2025

Phase III

C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

2024-519369-24-00METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Pfizer Inc.

Not possible to specify

Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece

22/12/2025

Phase III

C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

2025-522093-36-00Cancer cachexia

Pfizer Inc.

Nutritional and Metabolic Diseases

Slovakia, Italy, Belgium, Germany, Spain, France, Bulgaria, Poland

16/12/2025

Phase II

C5001004 - A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension

2025-521155-23-00Pulmonary Arterial Hypertension

Pfizer Inc.

Cardiovascular Diseases

Italy, Czechia, Germany, Greece, Spain, Belgium, France

02/12/2025

Phase I

A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition

2025-520763-41-00Older adults at risk of malnutrition

Pfizer Inc.

Not possible to specify

Spain

19/11/2025

Phase I/II

C5731006 - A PHASE 1B/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER

2025-521003-52-00HER2 Expressing Advanced Breast Cancer

Pfizer Inc.

Neoplasms

Germany, Spain, Italy

18/11/2025

Phase III

C1091009 - A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS

2022-503070-36-00Group B streptococcus (GBS) disease

Pfizer Inc.

Bacterial Infections and Mycoses

Finland, Netherlands, Spain

18/11/2025

Phase III

C5851005 - PADLINK-005: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

2025-521281-97-00Non-Small Cell Lung Cancer (NSCLC)

Pfizer Inc.

Neoplasms

Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria

17/11/2025

Phase III

C4551002 - An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

2025-520566-22-00Hormone Receptor-Positive, HER2-Negative Advanced/Metastati…

Pfizer Inc.

Neoplasms

Hungary, Bulgaria, Czechia, Slovakia, Netherlands, Spain, Greece, Finland, Belgium, Sweden, Poland, Germany, France, Italy

20/10/2025

Phase III

B7981027 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA

2024-515438-33-00Alopecia areata

Pfizer Inc.

Immune System Diseases

Spain, France, Czechia, Italy, Poland

14/10/2025

Phase III

B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

2024-515439-31-00Alopecia areata

Pfizer Inc.

Immune System Diseases

Italy, France, Czechia, Poland, Spain

14/10/2025

Phase I

A Study to Learn How Different Forms of The Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults

2025-522574-36-00Primary and secondary hypertension, and heart failure

Pfizer Inc.

Cardiovascular Diseases

Belgium

10/10/2025

Phase II

C4921003 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched-Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948 in Adults with Heart Failure (BRANCH-HF)

2024-518438-94-00Heart failure

Pfizer Inc.

Cardiovascular Diseases

France, Spain, Bulgaria, Poland, Hungary, Czechia

08/10/2025

Phase III

C4951063: An interventional efficacy and safety, Phase 3, double-blind, parallel group study to investigate intermittent prevention of Menstrual Migraine with Rimegepant compared with placebo in women participants 18 to 45 years of age

2024-517121-10-00Menstrual Migraine

Pfizer Inc.

Nervous System Diseases

Netherlands, Italy, Poland, Denmark, Germany, Spain

06/10/2025

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 6 November 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,777 trial records at the last sync on 06 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 50 of those trials that match the filters currently applied.

How many clinical trials does CTIS hold?

CTIS held 12,777 trial records at the last sync. Of the 2,556 most recently authorised trials shown in this register, 789 are Phase III, and 50 match the filters currently applied. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase, 50 trials
Phase	Trials	Share
Phase III	19	38%
Phase I	17	34%
Phase II	9	18%
Phase I/II	5	10%

Most active sponsors

Lead sponsors with the most trials
Lead sponsor	Trials
Pfizer Inc.	50

Member states with the most trials

Member states by number of trials with a site there
Member state	Trials
Spain	34
France	26
Germany	23
Italy	23
Poland	22
Belgium	17
Czechia	10
Greece	9
Bulgaria	8
Netherlands	8

→

Browse trials by member state

Spain (1075) France (930) Germany (898) Italy (778) Poland (619) Netherlands (547) Belgium (455) Czechia (341) Denmark (319) Hungary (254) Greece (237) Austria (219) Romania (219) Bulgaria (218) Sweden (200)

→

Browse trials by condition

Advanced solid tumors (23) Atopic Dermatitis (19) Non-Small Cell Lung Cancer (15) Obesity (14) Parkinson’s disease (14) Multiple sclerosis (13) Rheumatoid arthritis (13) Breast Cancer (11) Ulcerative colitis (11) Prostate Cancer (10)

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.